TIL Therapies Market Report and Forecast 2025-2034
Description
The global TIL therapies market was valued at USD 10.20 Million in 2024, driven by the growing incidence of cancer and the advancements in immunotherapy across the globe. The market is anticipated to grow at a CAGR of 12.00% during the forecast period of 2025-2034, with the values likely to reach USD 31.68 Million by 2034.
TIL Therapies Market Overview
Tumor-infiltrating lymphocytes (TIL) therapies are a form of therapy that involves drawing immune cells, specifically T lymphocytes, from a patient's tumor, expanding the cells in a lab, and reinfusing them to target cancer cells. This approach is aimed at boosting the body's natural defense mechanism against tumors, offering promise for treating cancers such as melanoma. The field of immuno-oncology is rapidly advancing, as it focuses on using the body's immune cells to fight cancer. The market is poised for significant growth, with breakthroughs in the treatment of cancer, growth in funding for research, and an increasing number of clinical trials. The market will undergo significant development with transformative targeted therapies.
TIL Therapies Market Growth Drivers
Growing Incidence of Cancer to Boost the Market Growth
The increasing incidence of cancer is one of the major growth drivers of the market. As per the World Health Organisation, in 2022, there were around 20 million new cancer cases, and 9.7 million deaths occurred globally. This rising prevalence necessitates advanced treatments. Innovative therapies such as TIL, which are more targeted and less invasive, are gaining importance and thus contributing to growth in the market.
Advancements in Immunotherapy to Drive the TIL Therapies Market Value
Advancements in immunotherapy are one of the crucial growth drivers for the market. Innovations in immune cell engineering and a greater understanding of the tumor microenvironment significantly enhance the results of therapy. They have the advantages of being highly personalized and targeted, as well as a higher success rate than standard methods. Their rising adoption is the driving force behind the market's growth.
TIL Therapies Market Trends
The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:
Rising Focus on Personalized Cancer Treatment
Personalized medicine is becoming increasingly popular in cancer treatment, and TIL therapies are at the forefront. These therapies are personalized for the patient, utilizing their immune cells to attack cancer cells. This trend indicates a growing preference for more precise treatments, that have fewer side effects, and higher therapeutic benefits. Personalized therapies are more effective and more satisfying to patients, which is why TIL therapies are becoming increasingly popular in clinical practice.
Adoption in Treating Solid Tumors to Boost TIL Therapies Market Value
TIL therapies have conventionally been applied in the treatment of melanoma. Recently, these therapies have gained increasing attention regarding other types of solid tumors like non-small cell lung cancer (NSCLC) and ovarian cancer. This shift could significantly broaden the market and provide new therapeutic options for patients with solid tumor malignancies.
Cost Reduction and Commercialization to Impact TIL Therapies Market Size Positively
The improvements in manufacturing processes are now slowly lowering the costs of TIL therapies. With decreasing costs, commercialization is rapidly gaining pace, and healthcare systems can easily adopt TIL therapies in routine treatment. This trend will make TIL therapies available to patients across the globe, increasing market penetration and adoption rates.
International Collaborations and Partnerships to Meet Rising TIL Therapies Market Demand
Collaborations between pharmaceutical companies, research institutions, and hospitals are becoming a key trend in the market. These partnerships allow for the pooling of resources, expertise, and technologies to accelerate the development and commercialization of TIL-based treatments. As more international alliances form, the global accessibility of TIL therapies is expected to expand, helping drive innovation and market growth.
TIL Therapies Market Segmentation
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Type of Cell
Segmentation Based on Type of Cell to Witness Substantial Growth
The market is segmented based on the type of cell including T-cells, B-cells, and natural killer cells. The T-cells are likely to account for a significant share of the market as they play a critical role in immune response. T-cells, particularly tumor-infiltrating lymphocytes, are one of the prime focuses of cancer immunotherapy, hence, showing high potential for various therapies in malignancies.
TIL Therapies Market Analysis by Region
The market is divided into regions such as North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. North America is a major shareholder in the market, driven by a strong health infrastructural framework, a high incidence of cancer, and significant investments in immunotherapy research. Europe is the other key region, based on the increasing adoption of sophisticated cancer treatments and growing collaboration in research. Both regions are central to the TIL therapies development in the global market.
Leading Players in the TIL Therapies Market
The key features of the market report comprise patent analysis, clinical trial analysis, grants analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
Autolus Therapeutics plc
Autolus Therapeutics is a United Kingdom-based company founded in 2014 and specializes in developing innovative T-cell therapies for cancer. It focuses on TIL therapies, and the lead product AUTO1, targeting acute lymphoblastic leukemia (ALL) has shown significant success. The company continues to advance CAR-T cell therapies, making a great contribution to TIL-based treatments for blood cancers.
Bellicum Pharmaceuticals, Inc.
Bellicum Pharmaceuticals was founded in the year 2004 with its headquarters in Houston, Texas. The company specializes in gene therapies and TIL technology for cancer treatment. It is known for its clinical developments in engineered T-cells, specifically those targeting solid tumors using the TIL-based approaches.
Eli Lilly and Company
Eli Lilly is a leader in pharmaceutical innovation which was founded in 1876 and has its headquarters in Indianapolis, Indiana. By acquiring Prevail Therapeutics and working with companies such as Precision Biosciences, Eli Lilly is advancing in the field of TIL therapies. Their contributions to the development of gene and cell-based immunotherapies can help shape the future landscape of cancer treatment.
Adaptimmune Therapeutics plc
Adaptimmune Therapeutics was founded in 2008 and is based in Oxford, United Kingdom. It is focused on the development of T-cell therapies, with a strong emphasis on TIL-based cancer treatments. Their novel approach, including engineered T-cells targeting specific tumor antigens, positions them as leaders in the immuno-oncology space. Their work on TIL therapies has been advancing personalized treatment options for various cancers.
Other key players in the market include Oxford Biomedica Plc., Precision Biosciences Inc., Seeking Alpha Ltd., Bluebird Bio, Inc., Fate Therapeutics Inc., and Merck KGaA.
Key Questions Answered in the TIL Therapies Market Report
TIL Therapies Market Overview
Tumor-infiltrating lymphocytes (TIL) therapies are a form of therapy that involves drawing immune cells, specifically T lymphocytes, from a patient's tumor, expanding the cells in a lab, and reinfusing them to target cancer cells. This approach is aimed at boosting the body's natural defense mechanism against tumors, offering promise for treating cancers such as melanoma. The field of immuno-oncology is rapidly advancing, as it focuses on using the body's immune cells to fight cancer. The market is poised for significant growth, with breakthroughs in the treatment of cancer, growth in funding for research, and an increasing number of clinical trials. The market will undergo significant development with transformative targeted therapies.
TIL Therapies Market Growth Drivers
Growing Incidence of Cancer to Boost the Market Growth
The increasing incidence of cancer is one of the major growth drivers of the market. As per the World Health Organisation, in 2022, there were around 20 million new cancer cases, and 9.7 million deaths occurred globally. This rising prevalence necessitates advanced treatments. Innovative therapies such as TIL, which are more targeted and less invasive, are gaining importance and thus contributing to growth in the market.
Advancements in Immunotherapy to Drive the TIL Therapies Market Value
Advancements in immunotherapy are one of the crucial growth drivers for the market. Innovations in immune cell engineering and a greater understanding of the tumor microenvironment significantly enhance the results of therapy. They have the advantages of being highly personalized and targeted, as well as a higher success rate than standard methods. Their rising adoption is the driving force behind the market's growth.
TIL Therapies Market Trends
The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:
Rising Focus on Personalized Cancer Treatment
Personalized medicine is becoming increasingly popular in cancer treatment, and TIL therapies are at the forefront. These therapies are personalized for the patient, utilizing their immune cells to attack cancer cells. This trend indicates a growing preference for more precise treatments, that have fewer side effects, and higher therapeutic benefits. Personalized therapies are more effective and more satisfying to patients, which is why TIL therapies are becoming increasingly popular in clinical practice.
Adoption in Treating Solid Tumors to Boost TIL Therapies Market Value
TIL therapies have conventionally been applied in the treatment of melanoma. Recently, these therapies have gained increasing attention regarding other types of solid tumors like non-small cell lung cancer (NSCLC) and ovarian cancer. This shift could significantly broaden the market and provide new therapeutic options for patients with solid tumor malignancies.
Cost Reduction and Commercialization to Impact TIL Therapies Market Size Positively
The improvements in manufacturing processes are now slowly lowering the costs of TIL therapies. With decreasing costs, commercialization is rapidly gaining pace, and healthcare systems can easily adopt TIL therapies in routine treatment. This trend will make TIL therapies available to patients across the globe, increasing market penetration and adoption rates.
International Collaborations and Partnerships to Meet Rising TIL Therapies Market Demand
Collaborations between pharmaceutical companies, research institutions, and hospitals are becoming a key trend in the market. These partnerships allow for the pooling of resources, expertise, and technologies to accelerate the development and commercialization of TIL-based treatments. As more international alliances form, the global accessibility of TIL therapies is expected to expand, helping drive innovation and market growth.
TIL Therapies Market Segmentation
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Type of Cell
- T-Cells
- B-Cells
- Natural Killer Cells
- Cervical Cancer
- Ovarian Cancer
- Kidney Cancer
- Gastrointestinal Cancer
- Head and Neck Cancers
- CD3
- CD8
- CD16
- CD56
- CD4
- CD57
- CD169
- CD68
- FOXP3
- Hospital
- Speciality Clinics
- Cancer Hospital
- Others
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Segmentation Based on Type of Cell to Witness Substantial Growth
The market is segmented based on the type of cell including T-cells, B-cells, and natural killer cells. The T-cells are likely to account for a significant share of the market as they play a critical role in immune response. T-cells, particularly tumor-infiltrating lymphocytes, are one of the prime focuses of cancer immunotherapy, hence, showing high potential for various therapies in malignancies.
TIL Therapies Market Analysis by Region
The market is divided into regions such as North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. North America is a major shareholder in the market, driven by a strong health infrastructural framework, a high incidence of cancer, and significant investments in immunotherapy research. Europe is the other key region, based on the increasing adoption of sophisticated cancer treatments and growing collaboration in research. Both regions are central to the TIL therapies development in the global market.
Leading Players in the TIL Therapies Market
The key features of the market report comprise patent analysis, clinical trial analysis, grants analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
Autolus Therapeutics plc
Autolus Therapeutics is a United Kingdom-based company founded in 2014 and specializes in developing innovative T-cell therapies for cancer. It focuses on TIL therapies, and the lead product AUTO1, targeting acute lymphoblastic leukemia (ALL) has shown significant success. The company continues to advance CAR-T cell therapies, making a great contribution to TIL-based treatments for blood cancers.
Bellicum Pharmaceuticals, Inc.
Bellicum Pharmaceuticals was founded in the year 2004 with its headquarters in Houston, Texas. The company specializes in gene therapies and TIL technology for cancer treatment. It is known for its clinical developments in engineered T-cells, specifically those targeting solid tumors using the TIL-based approaches.
Eli Lilly and Company
Eli Lilly is a leader in pharmaceutical innovation which was founded in 1876 and has its headquarters in Indianapolis, Indiana. By acquiring Prevail Therapeutics and working with companies such as Precision Biosciences, Eli Lilly is advancing in the field of TIL therapies. Their contributions to the development of gene and cell-based immunotherapies can help shape the future landscape of cancer treatment.
Adaptimmune Therapeutics plc
Adaptimmune Therapeutics was founded in 2008 and is based in Oxford, United Kingdom. It is focused on the development of T-cell therapies, with a strong emphasis on TIL-based cancer treatments. Their novel approach, including engineered T-cells targeting specific tumor antigens, positions them as leaders in the immuno-oncology space. Their work on TIL therapies has been advancing personalized treatment options for various cancers.
Other key players in the market include Oxford Biomedica Plc., Precision Biosciences Inc., Seeking Alpha Ltd., Bluebird Bio, Inc., Fate Therapeutics Inc., and Merck KGaA.
Key Questions Answered in the TIL Therapies Market Report
- What was the TIL therapies market value in 2024?
- What is the TIL therapies market forecast outlook for 2025-2034?
- What are the regional markets covered in the EMR report?
- What is the market segmentation based on the type of cell?
- What is the market segmentation based on indication?
- What is the market breakup based on target antigen?
- What is the market breakup based on the end user?
- What major factors aid the TIL therapies market demand?
- How has the market performed so far and how is it anticipated to perform in the coming years?
- What are the major drivers, opportunities, and restraints in the market?
- What are the major trends that influence the market?
- Which regional market is expected to dominate the market share in the forecast period?
- Which country is likely to experience elevated growth during the forecast period?
- Who are the key players involved in the TIL therapies market?
- What are the current unmet needs and challenges in the market?
- How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?
Table of Contents
400 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Global TIL Therapies Market Overview
- 3.1 Global TIL Therapies Market Historical Value (2018-2024)
- 3.2 Global TIL Therapies Market Forecast Value (2025-2034)
- 4 Vendor Positioning Analysis
- 4.1 Key Vendors
- 4.2 Prospective Leaders
- 4.3 Niche Leaders
- 4.4 Disruptors
- 5 Global TIL Therapies Market Landscape*
- 5.1 Global TIL Therapies Market: Developers Landscape
- 5.1.1 Analysis by Year of Establishment
- 5.1.2 Analysis by Company Size
- 5.1.3 Analysis by Region
- 5.2 Global TIL Therapies Market: Product Landscape
- 5.2.1 Analysis by Type of Cell
- 5.2.2 Analysis by Indication
- 5.2.3 Analysis by Target Antigen
- 6 Global TIL Therapies Market Dynamics
- 6.1 Market Drivers and Constraints
- 6.2 SWOT Analysis
- 6.2.1 Strengths
- 6.2.2 Weaknesses
- 6.2.3 Opportunities
- 6.2.4 Threats
- 6.3 PESTEL Analysis
- 6.3.1 Political
- 6.3.2 Economic
- 6.3.3 Social
- 6.3.4 Technological
- 6.3.5 Legal
- 6.3.6 Environment
- 6.4 Porter’s Five Forces Model
- 6.4.1 Bargaining Power of Suppliers
- 6.4.2 Bargaining Power of Buyers
- 6.4.3 Threat of New Entrants
- 6.4.4 Threat of Substitutes
- 6.4.5 Degree of Rivalry
- 6.5 Key Demand Indicators
- 6.6 Key Price Indicators
- 6.7 Industry Events, Initiatives, and Trends
- 6.8 Value Chain Analysis
- 7 Global TIL Therapies Market Segmentation (218-2034)
- 7.1 Global TIL Therapies Market (2018-2034) by Type of Cell
- 7.1.1 Market Overview
- 7.1.2 T-Cells
- 7.1.3 B-Cells
- 7.1.4 Natural Killer Cells
- 7.2 Global TIL Therapies Market (2018-2034) by Indication
- 7.2.1 Market Overview
- 7.2.2 Cervical Cancer
- 7.2.3 Ovarian Cancer
- 7.2.4 Kidney Cancer
- 7.2.5 Gastrointestinal Cancer
- 7.2.6 Head and Neck Cancers
- 7.3 Global TIL Therapies Market (2018-2034) by Target Antigen
- 7.3.1 Market Overview
- 7.3.2 CD3
- 7.3.3 CD8
- 7.3.4 CD16
- 7.3.5 CD56
- 7.3.6 CD4
- 7.3.7 CD57
- 7.3.8 CD169
- 7.3.9 CD68
- 7.3.10 FOXP3
- 7.4 Global TIL Therapies Market (2018-2034) by End User
- 7.4.1 Market Overview
- 7.4.2 Hospital
- 7.4.3 Specialty Clinics
- 7.4.4 Cancer Hospital
- 7.4.5 Others
- 7.5 Global TIL Therapies Market (2018-2034) by Region
- 7.5.1 Market Overview
- 7.5.2 North America
- 7.5.3 Europe
- 7.5.4 Asia Pacific
- 7.5.5 Latin America
- 7.5.6 Middle East and Africa
- 8 North America TIL Therapies Market (218-2034)
- 8.1 North America TIL Therapies Market (2018-2034) by Type of Cell
- 8.1.1 Market Overview
- 8.1.2 T-Cells
- 8.1.3 B-Cells
- 8.1.4 Natural Killer Cells
- 8.2 North America TIL Therapies Market (2018-2034) by Indication
- 8.2.1 Market Overview
- 8.2.2 Cervical Cancer
- 8.2.3 Ovarian Cancer
- 8.2.4 Kidney Cancer
- 8.2.5 Gastrointestinal Cancer
- 8.2.6 Head and Neck Cancers
- 8.3 North America TIL Therapies Market (2018-2034) by Target Antigen
- 8.3.1 Market Overview
- 8.3.2 CD3
- 8.3.3 CD8
- 8.3.4 CD16
- 8.3.5 CD56
- 8.3.6 CD4
- 8.3.7 CD57
- 8.3.8 CD169
- 8.3.9 CD68
- 8.3.10 FOXP3
- 8.4 North America TIL Therapies Market (2018-2034) by End User
- 8.4.1 Market Overview
- 8.4.2 Hospital
- 8.4.3 Specialty Clinics
- 8.4.4 Cancer Hospital
- 8.4.5 Others
- 8.5 North America TIL Therapies Market (2018-2034) by Country
- 8.5.1 United States of America
- 8.5.1.1 United States of America TIL Therapies Market (2018-2034) by Type of Cell
- 8.5.1.2 Canada TIL Therapies Market (2018-2034) by Type of Cell
- 9 Europe TIL Therapies Market (218-2034)
- 9.1 Europe TIL Therapies Market (2018-2034) by Type of Cell
- 9.1.1 Market Overview
- 9.1.2 T-Cells
- 9.1.3 B-Cells
- 9.1.4 Natural Killer Cells
- 9.2 Europe TIL Therapies Market (2018-2034) by Indication
- 9.2.1 Market Overview
- 9.2.2 Cervical Cancer
- 9.2.3 Ovarian Cancer
- 9.2.4 Kidney Cancer
- 9.2.5 Gastrointestinal Cancer
- 9.2.6 Head and Neck Cancers
- 9.3 Europe TIL Therapies Market (2018-2034) by Target Antigen
- 9.3.1 Market Overview
- 9.3.2 CD3
- 9.3.3 CD8
- 9.3.4 CD16
- 9.3.5 CD56
- 9.3.6 CD4
- 9.3.7 CD57
- 9.3.8 CD169
- 9.3.9 CD68
- 9.3.10 FOXP3
- 9.4 Europe TIL Therapies Market (2018-2034) by End User
- 9.4.1 Market Overview
- 9.4.2 Hospital
- 9.4.3 Specialty Clinics
- 9.4.4 Cancer Hospital
- 9.4.5 Others
- 9.5 Europe TIL Therapies Market (2018-2034) by Country
- 9.5.1 United Kingdom
- 9.5.1.1 United Kingdom TIL Therapies Market (2018-2034) by Type of Cell
- 9.5.2 Germany
- 9.5.2.1 Germany TIL Therapies Market (2018-2034) by Type of Cell
- 9.5.3 France
- 9.5.3.1 France TIL Therapies Market (2018-2034) by Type of Cell
- 9.5.4 Italy
- 9.5.4.1 Italy TIL Therapies Market (2018-2034) by Type of Cell
- 9.5.5 Others
- 10 Asia Pacific TIL Therapies Market (218-2034)
- 10.1 Asia Pacific TIL Therapies Market (2018-2034) by Type of Cell
- 10.1.1 Market Overview
- 10.1.2 T-Cells
- 10.1.3 B-Cells
- 10.1.4 Natural Killer Cells
- 10.2 Asia Pacific TIL Therapies Market (2018-2034) by Indication
- 10.2.1 Market Overview
- 10.2.2 Cervical Cancer
- 10.2.3 Ovarian Cancer
- 10.2.4 Kidney Cancer
- 10.2.5 Gastrointestinal Cancer
- 10.2.6 Head and Neck Cancers
- 10.3 Asia Pacific TIL Therapies Market (2018-2034) by Target Antigen
- 10.3.1 Market Overview
- 10.3.2 CD3
- 10.3.3 CD8
- 10.3.4 CD16
- 10.3.5 CD56
- 10.3.6 CD4
- 10.3.7 CD57
- 10.3.8 CD169
- 10.3.9 CD68
- 10.3.10 FOXP3
- 10.4 Asia Pacific TIL Therapies Market (2018-2034) by End User
- 10.4.1 Market Overview
- 10.4.2 Hospital
- 10.4.3 Specialty Clinics
- 10.4.4 Cancer Hospital
- 10.4.5 Others
- 10.5 Asia Pacific TIL Therapies Market (2018-2034) by Country
- 10.5.1 China
- 10.5.1.1 China TIL Therapies Market (2018-2034) by Type of Cell
- 10.5.2 Japan
- 10.5.2.1 Japan TIL Therapies Market (2018-2034) by Type of Cell
- 10.5.3 India
- 10.5.3.1 India TIL Therapies Market (2018-2034) by Type of Cell
- 10.5.4 ASEAN
- 10.5.4.1 ASEAN TIL Therapies Market (2018-2034) by Type of Cell
- 10.5.5 Australia
- 10.5.5.1 Australia TIL Therapies Market (2018-2034) by Type of Cell
- 10.5.6 Others
- 11 Latin America TIL Therapies Market (218-2034)
- 11.1 Latin America TIL Therapies Market (2018-2034) by Type of Cell
- 11.1.1 Market Overview
- 11.1.2 T-Cells
- 11.1.3 B-Cells
- 11.1.4 Natural Killer Cells
- 11.2 Latin America TIL Therapies Market (2018-2034) by Indication
- 11.2.1 Market Overview
- 11.2.2 Cervical Cancer
- 11.2.3 Ovarian Cancer
- 11.2.4 Kidney Cancer
- 11.2.5 Gastrointestinal Cancer
- 11.2.6 Head and Neck Cancers
- 11.3 Latin America TIL Therapies Market (2018-2034) by Target Antigen
- 11.3.1 Market Overview
- 11.3.2 CD3
- 11.3.3 CD8
- 11.3.4 CD16
- 11.3.5 CD56
- 11.3.6 CD4
- 11.3.7 CD57
- 11.3.8 CD169
- 11.3.9 CD68
- 11.3.10 FOXP3
- 11.4 Latin America TIL Therapies Market (2018-2034) by End User
- 11.4.1 Market Overview
- 11.4.2 Hospital
- 11.4.3 Speciality Clinics
- 11.4.4 Cancer Hospital
- 11.4.5 Others
- 11.5 Latin America TIL Therapies Market (2018-2034) by Country
- 11.5.1 Brazil
- 11.5.1.1 Brazil TIL Therapies Market (2018-2034) by Type of Cell
- 11.5.2 Argentina
- 11.5.2.1 Argentina TIL Therapies Market (2018-2034) by Type of Cell
- 11.5.3 Mexico
- 11.5.3.1 Mexico TIL Therapies Market (2018-2034) by Type of Cell
- 11.5.4 Others
- 12 Middle East and Africa TIL Therapies Market (218-2034)
- 12.1 Middle East and Africa TIL Therapies Market (2018-2034) by Type of Cell
- 12.1.1 Market Overview
- 12.1.2 T-Cells
- 12.1.3 B-Cells
- 12.1.4 Natural Killer Cells
- 12.2 Middle East and Africa TIL Therapies Market (2018-2034) by Indication
- 12.2.1 Market Overview
- 12.2.2 Cervical Cancer
- 12.2.3 Ovarian Cancer
- 12.2.4 Kidney Cancer
- 12.2.5 Gastrointestinal Cancer
- 12.2.6 Head and Neck Cancers
- 12.3 Middle East and Africa TIL Therapies Market (2018-2034) by Target Antigen
- 12.3.1 Market Overview
- 12.3.2 CD3
- 12.3.3 CD8
- 12.3.4 CD16
- 12.3.5 CD56
- 12.3.6 CD4
- 12.3.7 CD57
- 12.3.8 CD169
- 12.3.9 CD68
- 12.3.10 FOXP3
- 12.4 Middle East and Africa TIL Therapies Market (2018-2034) by End User
- 12.4.1 Market Overview
- 12.4.2 Hospital
- 12.4.3 Speciality Clinics
- 12.4.4 Cancer Hospital
- 12.4.5 Others
- 12.5 Middle East and Africa TIL Therapies Market (2018-2034) by Country
- 12.5.1 Saudi Arabia
- 12.5.1.1 Saudi Arabia TIL Therapies Market (2018-2034) by Type of Cell
- 12.5.2 United Arab Emirates
- 12.5.2.1 United Arab Emirates TIL Therapies Market (2018-2034) by Type of Cell
- 12.5.3 Nigeria
- 12.5.3.1 Nigeria TIL Therapies Market (2018-2034) by Type of Cell
- 12.5.4 South Africa
- 12.5.4.1 South Africa TIL Therapies Market (2018-2034) by Type of Cell
- 12.5.5 Others
- 13 Regulatory Framework
- 13.1 Regulatory Overview
- 13.2 US FDA
- 13.3 EU EMA
- 13.4 Japan PMDA
- 13.5 India CDSCO
- 13.6 Others
- 14 Patent Analysis
- 14.1 Analysis by Type of Patent
- 14.2 Analysis by Publication Year
- 14.3 Analysis by Issuing Authority
- 14.4 Analysis by Patent Age
- 14.5 Analysis by CPC Analysis
- 14.6 Analysis by Patent Valuation
- 15 Clinical Trials Analysis
- 15.1 Analysis by Trial Registration Year
- 15.2 Analysis by Trial Status
- 15.3 Analysis by Trial Phase
- 15.4 Analysis by Therapeutic Area
- 15.5 Analysis by Geography
- 16 Grants Analysis
- 16.1 Analysis by Year
- 16.2 Analysis by Amount Awarded
- 16.3 Analysis by Issuing Authority
- 16.4 Analysis by Grant Application
- 16.5 Analysis by Funding Institute
- 16.6 Analysis by NIH Departments
- 16.7 Analysis by Recipient Organization
- 17 Funding and Investment Analysis
- 17.1 Analysis by Funding Instances
- 17.2 Analysis by Drug Class of Funding
- 17.3 Analysis by Funding Amount
- 17.4 Analysis by Leading Players
- 17.5 Analysis by Leading Investors
- 17.6 Analysis by Geography
- 18 Strategic Initiatives
- 18.1 Analysis by Partnership Instances
- 18.2 Analysis by Drug Class of Partnership
- 18.3 Analysis by Leading Players
- 18.4 Analysis by Geography
- 19 Supplier Landscape
- 19.1 Market Share Analysis, By Region (Top 5 Companies)
- 19.1.1 Market Share Analysis: Global
- 19.1.2 Market Share Analysis: North America
- 19.1.3 Market Share Analysis: Europe
- 19.1.4 Market Share Analysis: Asia Pacific
- 19.1.5 Market Share Analysis: Others
- 19.2 Autolus Therapeutics plc
- 19.2.1 Financial Analysis
- 19.2.2 Product Portfolio
- 19.2.3 Demographic Reach and Achievements
- 19.2.4 Company News and Development
- 19.2.5 Certifications
- 19.3 Bellicum Pharmaceuticals, Inc.
- 19.3.1 Financial Analysis
- 19.3.2 Product Portfolio
- 19.3.3 Demographic Reach and Achievements
- 19.3.4 Company News and Development
- 19.3.5 Certifications
- 19.4 Eli Lilly and Company
- 19.4.1 Financial Analysis
- 19.4.2 Product Portfolio
- 19.4.3 Demographic Reach and Achievements
- 19.4.4 Company News and Development
- 19.4.5 Certifications
- 19.5 Oxford Biomedica Plc.
- 19.5.1 Financial Analysis
- 19.5.2 Product Portfolio
- 19.5.3 Demographic Reach and Achievements
- 19.5.4 Company News and Development
- 19.5.5 Certifications
- 19.6 Precision Biosciences Inc.
- 19.6.1 Financial Analysis
- 19.6.2 Product Portfolio
- 19.6.3 Demographic Reach and Achievements
- 19.6.4 Company News and Development
- 19.6.5 Certifications
- 19.7 Seeking Alpha Ltd.
- 19.7.1 Financial Analysis
- 19.7.2 Product Portfolio
- 19.7.3 Demographic Reach and Achievements
- 19.7.4 Company News and Development
- 19.7.5 Certifications
- 19.8 Bluebird Bio, Inc.
- 19.8.1 Financial Analysis
- 19.8.2 Product Portfolio
- 19.8.3 Demographic Reach and Achievements
- 19.8.4 Company News and Development
- 19.8.5 Certifications
- 19.9 Adaptimmune Therapeutics plc
- 19.9.1 Financial Analysis
- 19.9.2 Product Portfolio
- 19.9.3 Demographic Reach and Achievements
- 19.9.4 Company News and Development
- 19.9.5 Certifications
- 19.10 Fate Therapeutics Inc.
- 19.10.1 Financial Analysis
- 19.10.2 Product Portfolio
- 19.10.3 Demographic Reach and Achievements
- 19.10.4 Company News and Development
- 19.10.5 Certifications
- 19.11 Merck KGaA
- 19.11.1 Financial Analysis
- 19.11.2 Product Portfolio
- 19.11.3 Demographic Reach and Achievements
- 19.11.4 Company News and Development
- 19.11.5 Certifications
- 20 Global TIL Therapies Market – Distribution Model (Additional Insight)
- 20.1 Overview
- 20.2 Potential Distributors
- 20.3 Key Parameters for Distribution Partner Assessment
- 21 Key Opinion Leaders (KOL) Insights (Additional Insight)
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
